ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
ClearPoint Neuro (NASDAQ:CLPT), a global device, cell, and gene therapy-enabling company focused on brain and spine navigation, has announced its participation in several major healthcare conferences during Q4 2024. The company's management will attend five significant events, including the UBS Global Healthcare Conference, Stifel Healthcare Conference, Canaccord Genuity Forum, Piper Sandler Healthcare Conference, and Stifel MedTech Madness West Coast Bus Tour. Additionally, President and CEO Joe Burnett's interview is featured on the Bloomberg Intelligence Vanguards of Healthcare Podcast, released on October 31, 2024.
ClearPoint Neuro (NASDAQ:CLPT), un'azienda globale focalizzata sulla navigazione del cervello e della colonna vertebrale attraverso dispositivi, terapie cellulari e geniche, ha annunciato la sua partecipazione a diverse importanti conferenze sanitarie durante il quarto trimestre del 2024. La direzione dell'azienda parteciperà a cinque eventi significativi, tra cui il UBS Global Healthcare Conference, il Stifel Healthcare Conference, il Canaccord Genuity Forum, il Piper Sandler Healthcare Conference e il Stifel MedTech Madness West Coast Bus Tour. Inoltre, l'intervista al Presidente e CEO Joe Burnett è presente nel podcast Bloomberg Intelligence Vanguards of Healthcare, rilasciato il 31 ottobre 2024.
ClearPoint Neuro (NASDAQ:CLPT), una empresa global dedicada a la navegación del cerebro y la columna vertebral a través de dispositivos, terapias celulares y genéticas, ha anunciado su participación en varias conferencias de salud importantes durante el cuarto trimestre de 2024. La dirección de la empresa asistirá a cinco eventos significativos, incluyendo la UBS Global Healthcare Conference, la Stifel Healthcare Conference, el Canaccord Genuity Forum, la Piper Sandler Healthcare Conference y el Stifel MedTech Madness West Coast Bus Tour. Además, la entrevista con el Presidente y CEO Joe Burnett se presenta en el podcast Bloomberg Intelligence Vanguards of Healthcare, lanzado el 31 de octubre de 2024.
ClearPoint Neuro (NASDAQ:CLPT)는 장치, 세포 및 유전자 치료를 통해 뇌 및 척추 내비게이션에 중점을 두고 있는 글로벌 회사로, 2024년 4분기 동안 여러 주요 의료 회의에 참여한다고 발표했습니다. 회사 경영진은 UBS 글로벌 의료 회의, Stifel 의료 회의, Canaccord Genuity 포럼, Piper Sandler 의료 회의, 그리고 Stifel MedTech Madness 서부 해안 버스 투어 등 다섯 가지 중요한 행사에 참석할 예정입니다. 또한, 사장 겸 CEO인 Joe Burnett의 인터뷰는 2024년 10월 31일에 출시된 Bloomberg Intelligence Vanguards of Healthcare 팟캐스트에 수록되어 있습니다.
ClearPoint Neuro (NASDAQ:CLPT), une entreprise mondiale spécialisée dans la navigation cérébrale et de la colonne vertébrale à travers des dispositifs, des thérapies cellulaires et géniques, a annoncé sa participation à plusieurs grandes conférences de santé au cours du quatrième trimestre 2024. La direction de l'entreprise assistera à cinq événements significatifs, notamment la UBS Global Healthcare Conference, la Stifel Healthcare Conference, le Canaccord Genuity Forum, la Piper Sandler Healthcare Conference et le Stifel MedTech Madness West Coast Bus Tour. De plus, l'interview du Président et CEO Joe Burnett est présentée dans le podcast Bloomberg Intelligence Vanguards of Healthcare, publié le 31 octobre 2024.
ClearPoint Neuro (NASDAQ:CLPT), ein global tätiges Unternehmen, das sich auf die Navigation von Gehirn und Wirbelsäule durch Geräte, Zell- und Gentherapien spezialisiert hat, hat seine Teilnahme an mehreren großen Gesundheitskonferenzen im vierten Quartal 2024 bekannt gegeben. Das Management des Unternehmens wird an fünf bedeutenden Veranstaltungen teilnehmen, darunter die UBS Global Healthcare Conference, die Stifel Healthcare Conference, das Canaccord Genuity Forum, die Piper Sandler Healthcare Conference und die Stifel MedTech Madness West Coast Bus Tour. Darüber hinaus wird das Interview mit Präsident und CEO Joe Burnett im Bloomberg Intelligence Vanguards of Healthcare Podcast veröffentlicht, das am 31. Oktober 2024 erscheint.
- None.
- None.
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today
SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.
Healthcare Conferences with Participation of ClearPoint Neuro Management Include:
UBS Global Healthcare Conference in Rancho Palos Verdes, CA on November 13, 2024
Stifel Healthcare Conference in New York City, NY on November 18 and 19, 2024
Piper Sandler 36th Annual Healthcare Conference in New York City, NY on December 4, 2024
Stifel MedTech Madness West Coast Bus Tour in Laguna Beach, CA on December 9, 2024
Members of the ClearPoint Neuro management team will be onsite and available for in-person investor meetings with those who are registered to attend the various conferences.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the context of the federal securities laws, which may include the Company's expectations for the future performance, revenues, and operating expenses, and the adequacy of cash and cash equivalent balances to support operations and meet future obligations. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2024, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which the Company intends to file with the Securities and Exchange Commission on or before November 14, 2024. The Company does not assume any obligation to update these forward-looking statements.
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
SOURCE: ClearPoint Neuro
View the original press release on accesswire.com
FAQ
What healthcare conferences will ClearPoint Neuro (CLPT) attend in Q4 2024?
Where can investors meet ClearPoint Neuro (CLPT) management in Q4 2024?
When was ClearPoint Neuro's (CLPT) CEO featured on Bloomberg Intelligence podcast?
